menu
    • menu

    Company profile for Resalis Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease. The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of...
    Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease. The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Resalis TherapeuticsItaly Flag
    Country
    Country
    Italy
    Address
    Address
    Via Nizza, 52, Turin, Piedmont 10126
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.resalistherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/resalistherapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Resalis Report Fat-Selective Weight Loss With RES-010 In Primates
    Resalis Report Fat-Selective Weight Loss With RES-010 In Primates

    07 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/07/3162283/0/en/Resalis-Therapeutics-Reports-Durable-Fat-Selective-Weight-Loss-with-RES-010-in-Non-Human-Primates-at-Multiple-Scientific-and-Industry-Meetings.html

    GLOBENEWSWIRE
    07 Oct 2025
    Share Share
    Resalis Begins Phase 1 Trial for RES-010 in Obesity
    Resalis Begins Phase 1 Trial for RES-010 in Obesity

    03 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241203530139/en

    BUSINESSWIRE
    03 Dec 2024
    Share Share
    Resalis Therapeutics Gains Strategic Equity Investment from Sanofi
    Resalis Therapeutics Gains Strategic Equity Investment from Sanofi

    28 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241028943917/en

    BUSINESSWIRE
    28 Oct 2024
    Share Share
    Resalis Appoints Almut Nitsche as Chief Medical and Development Officer
    Resalis Appoints Almut Nitsche as Chief Medical and Development Officer

    01 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240201932935/en

    BUSINESSWIRE
    01 Feb 2024
    Share Share
    Resalis Therapeutics Raises €10 Million Series A
    Resalis Therapeutics Raises €10 Million Series A

    04 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240104751575/en

    BUSINESSWIRE
    04 Jan 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search